Sep 20, 2019
CHMP Recommends Approval of Dupixent® (dupilumab) for Severe Chronic Rhinosinusitis with Nasal Polyposis
Sep 18, 2019
Educational Campaign Helps Teens and Their Caregivers Tackle Everyday Challenges of Living with Moderate-to-severe Atopic Dermatitis
Sep 12, 2019
Zinc Paste Bandage Market to Surpass US$ 2,469.2 Million by 2026 - Coherent Market Insights
Sep 06, 2019
Hoth Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference and RESI 2019 Boston Conference
Sep 06, 2019
Recent Studies Reveal Flare Rates Among Dupixent-Treated Patients with Moderate-to-Severe Atopic Dermatitis
Aug 19, 2019
Eczema Impacts Physical and Mental Health of 31M Americans
Aug 06, 2019
Dupixent® (dupilumab) Approved by European Commission for Adolescents with Moderate-to-Severe Atopic Dermatitis
Aug 06, 2019
Dupixent® (dupilumab) Showed Positive Topline Results in Phase 3 Trial of Children Aged 6 to 11 Years with Severe Atopic Dermatitis
Jul 29, 2019
Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study of its Interleukin-31 Monoclonal Antibody for the Treatment of Atopic Dermatitis in Dogs
Jul 25, 2019
Almirall Issues Call For Grant Submissions For Development of New Immunodermatology Therapies
Jul 24, 2019
Allergic Diseases: Pipeline Offers Novel Approaches to Treat Increasingly Prevalent Conditions, with Strong Presence of Cytokine Mediators Among First-in-Class Products
Jun 28, 2019
CHMP Recommends Approval of Dupixent® (dupilumab) for Moderate-to-Severe Atopic Dermatitis in Adolescents
Jun 21, 2019
Regeneron and Sanofi Announce Positive Topline Phase 2 Results for IL-33 Antibody in Asthma
Jun 20, 2019
Edesa Biotech Receives Approval to Proceed with U.S. Clinical Study
Jun 18, 2019
Medimetriks Pharmaceuticals Focuses on Advancing MM36 (difamilast) Through Phase 3 Trials; Extinguishes Debt Owed to Knight Therapeutics
Jun 13, 2019
Hoth Therapeutics to Present to Investors at the Union League of Philadelphia
Jun 11, 2019
Biotech Brief: Atopic Dermatitis (Eczema) Revenues Projected to Exceed $6 Billion by 2022
Jun 11, 2019
Newly Published Research Shows CLn® BodyWash Significantly Improves Moderate-to-Severe Atopic Dermatitis in Infants, Children and Adolescents
Jun 10, 2019
Hoth Therapeutics to Begin Production of BioLexa Therapeutic for Upcoming Toxicology and Clinical Trials
Jun 06, 2019
Hoth Therapeutics Forms Wholly Owned Australian Subsidiary, in Preparation of Upcoming Clinical Trials for Atopic Dermatitis Solution